跳转至内容
Merck

SML0534

Sigma-Aldrich

维替泊芬

≥94% (HPLC), powder, YAP-TEA domain interaction inhibitor

别名:

反式-18-乙烯基-4,4a-二氢-3,4-双(甲氧羰基)-4a,8,14,19-四甲基-23H,25H-苯并[b]卟吩-9,13-二丙酸单甲酯, 维速达尔, (4R,4aS)-rel-18-乙烯基-4,4a-二氢-3,4-双(甲氧羰基)-4a,8,14,19-四甲基-24H,26H-苯并[b]卟吩-9,13-二丙酸单甲酯

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C41H42N4O8
分子量:
718.79
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

product name

维替泊芬, ≥94% (HPLC)

化驗

≥94% (HPLC)

形狀

powder

儲存條件

desiccated
protect from light

溶解度

DMSO: 2 mg/mL, clear (warmed)

儲存溫度

−20°C

SMILES 字串

CC(C(/C=C1[C@@]2(C)C(/C(N/1)=C/3)=CC=C(C(OC)=O)[C@H]2C(OC)=O)=N/4)=C(CCC(OC)=O)C4=C\C5=C(CCC(O)=O)C(C)=C(/C=C6C(C=C)=C(C)C3=N/6)N5.CC(C(/C=C7[C@@]8(C)C(/C(N/7)=C/9)=CC=C(C(OC)=O)[C@H]8C(OC)=O)=N/%10)=C(CCC(O)=O)C%10=C\C%11=C(CCC(OC)=O)C(C)=C(/C=C%12C(C=C)

InChI

1S/2C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)24(11-14-36(46)47)32(44-30)18-33-25(12-15-37(48)51-6)21(3)28(43-33)16-31(23)42-29;1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h2*9-10,13,16-19,38,43,45H,1,11-12,14-15H2,2-8H3,(H,46,47)/b31-16-,32-18-,34-17-,35-19-;31-16-,33-18-,34-17-,35-19-/t2*38-,41+/m00/s1

InChI 密鑰

YHNBVDZVUQFVLS-SKJZPIBWSA-N

正在寻找类似产品? 访问 产品对比指南

應用

维替泊芬已被用作光敏剂。它还可用作YAP(Yes-相关蛋白)-TEA结构域(TEAD)相互作用的抑制剂。

生化/生理作用

维替泊芬具有破坏YAP(Yes-相关蛋白)/TAZ(具有PDZ结合基序的转录共激活因子)和TEA结构域(TEAD)复合物之间的相互作用的能力。它还可降低卵巢癌细胞的活力,并几乎消除细胞迁移。因此,维替泊芬被认为是治疗卵巢癌的有效方法。
维替泊芬是一种用于光动力疗法的光敏剂,可用于消除与黄斑变性等病症相关的眼内异常血管。维替泊芬可在异常血管中积聚,当在氧气存在下被波长为693nm的非热红光刺激时,可产生高反应性的短寿命单线态氧和其他活性氧自由基,从而导致局部内皮损伤和血管阻塞。维替泊芬主要定位于线粒体中。

其他說明

光敏感

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Alan F Cruess et al.
Acta ophthalmologica, 87(2), 118-132 (2008-06-26)
Photodynamic therapy (PDT) with verteporfin has been used less comprehensively in the treatment of exudative age-related macular degeneration (AMD), and specifically of choroidal neovascularization (CNV), since the advent of antiangiogenic therapies. Recently, there has been a renewed interest in PDT
Kevin Tozer et al.
Ophthalmology, 120(10), 2029-2034 (2013-05-30)
To examine the outcomes of combination anti-vascular endothelial growth factor (VEGF) and photodynamic therapy (PDT) for the treatment of neovascular age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy. Retrospective, interventional case series. Twenty-six eyes of 26 patients treated with anti-VEGF
Wai Man Chan et al.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 248(5), 613-626 (2010-02-18)
Verteporfin photodynamic therapy (PDT) is approved for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), as well as for subfoveal CNV due to pathologic myopia and ocular histoplasmosis syndrome. Verteporfin PDT addresses the
Victor C K Lo et al.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 31(9), 1398-1405 (2013-04-30)
Photodynamic therapy (PDT) has been shown to ablate tumors within vertebral bone and yield short-term improvements in vertebral architecture and biomechanical strength, in particular when combined with bisphosphonate (BP) treatment. Longer-term outcomes of PDT combined with current treatments for skeletal
Akihiro Yamashita et al.
Stem cells translational medicine, 10(1), 115-127 (2020-08-22)
Human induced pluripotent stem cells (hiPSCs) are a promising cell source for the creation of cartilage to treat articular cartilage damage. The molecular mechanisms that translate culture conditions to the chondrogenic differentiation of hiPSCs remain to be analyzed. To analyze

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门